Wire · regulatory
The Libre Duo Authorization Signals a New FDA Posture on Dual-Biomarker Wearables
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 November 2026 · Fusion42 review
The FDA authorized the Libre Duo, the first continuous wearable monitoring both ketone and glucose levels simultaneously, via the De Novo pathway creating a new regulatory predicate for dual-biomarker devices. This signals a shift toward accepting integrated physiological data in diabetes trials and expands patient monitoring to include pediatric populations from age 2.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You must rethink your diabetes device development as the FDA just created a new approved class for dual-biomarker wearables. Devices that measure multiple metabolic signals together now have a faster path to market, pushing you to innovate around integrated monitoring or risk falling behind.
◆ Coverage
1 source · 4 Nov 2026
◆ Related on Wire
◆ Topics